Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,464.88 -4.42 (-0.08%) Dow
38,944.00 -168.16 (-0.43%) Nasdaq
17,762.64 +44.99 (+0.25%) Bitcoin USD
61,860.11 +594.75 (+0.97%) CMC Crypto 200
1,279.66 -4.12 (-0.32%)
ITCI Jan 2025 75.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:16AM EDT. Market open.
| Previous close | 8.60 |
| Open | 8.60 |
| Bid | 7.60 |
| Ask | 8.70 |
| Strike | 75.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.60 - 8.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 112 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.